Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of
erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected
to participate for up to 30 weeks. Eligible patients will be randomised to receive either
MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.